U.S. stock market midday update: Pomdoctor fell 18.84%, trading volume increased, market sentiment fluctuations have drawn attention, and future trends need to be observed cautiously

U.S. Stock Market Midday Update Pomdoctor, down 18.84%, with increased trading volume and no significant news recently. Trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. Stocks with High Trading Volume in the Industry McKesson up 1.15%. Based on recent news, On May 9, McKesson announced strong performance in its core business, reflecting the advantages of its growth strategy and the value of its differentiated product portfolio. The company is in a strong position entering fiscal year 2027, with clear business momentum expected to continue creating long-term value for customers, partners, and shareholders. This news boosted investor confidence and drove the stock price up. On May 9, analysts adjusted the target price for McKesson's stock, lowering the average target price from $997.53 to $962.6. Nevertheless, analysts maintained a "Buy" rating, believing the stock has about 28% potential upside. Analysts' optimistic expectations further supported the stock price increase. On May 11, MarketBeat reported that although McKesson currently has a "Moderate Buy" rating among analysts, top analysts believe there are five stocks that are more worthy of purchase than McKesson. This news may have impacted some investors, but overall it did not prevent the stock price from rising. Recent industry performance has been strong, with clear capital inflows, though risks need to be monitored. Cencora up 1.15%. Cencora up 1.15%. No significant news recently; trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. no_news Cardinal Health up 0.64%. Based on recent news, On May 9, market analysts noted that although Cardinal Health has a Moderate Buy rating, it was not included in the top recommended stocks list. This indicates that despite Cardinal Health's good performance, the market is cautious about its future growth potential, affecting investor confidence. On May 9, market analysts pointed out that five stocks are considered better investment choices, which may lead to some capital flowing out of Cardinal Health and into these more attractive stocks. No other significant news recently. Market analysts are cautious about Cardinal Health, with capital flowing to other stocks. Stocks with High Market Capitalization in the Industry Henry Schein up 1.17%. Based on recent news, On May 11, Henry Schein gained control of S.I.N. 360 U.S. distributor through a transaction, triggering a $11 million remeasurement gain, approximately $0.07 diluted earnings per share. Management indicated that more joint ventures may be integrated in the future, but any additional gains are expected to materialize in the second half of 2026. No other significant news recently. Trading is active, with clear capital flow